March 2021: Expanded, population-level access to PrEP through the SEARCH study, with a flexible service delivery model, associated with lower HIV incidence among PrEP initiators in rural communities in Kenya and Uganda

Mar 30, 2021

Article: HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. Published in: PLoS Med. 2021;18(2):e1003492 https://doi.org/10.1371/journal.pmed.1003492 Authors: Koss CA,...

Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study

Mar 26, 2021

Chammartin F, Lodi S, Logan R, Ryom L, Mocroft A, Kirk O, d’Arminio Monforte A, Reiss P, Phillips A, El-Sadr W, Hatleberg CI, Pradier C, Bonnet F, Law M, De Wit S, Sabin C, Lundgren JD, Bucher HC. Ann Intern Med. 2021 Mar 16. doi: 10.7326/M20-5226. Epub ahead...

Patient feedback surveys among pregnant women in Eswatini to improve antenatal care retention

Mar 26, 2021

Teasdale CA, Geller A, Shongwe S, Mafukidze A, Choy M, Magaula B, Yuengling K, King K, De Gusmao EP, Ryan C, Ao T, Callahan T, Modi S, Abrams EJ. PLoS One. 2021 Mar 24;16(3):e0248685. doi: 10.1371/journal.pone.0248685. PMID: 33760864. Abstract Background: Uptake and...

February 2021: Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study

Feb 23, 2021

Article: Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study Published in: Lancet HIV. 2021;8(2):e87-e95 https://doi.org/10.1016/S2352-3018(20)30304-0 Authors: Baeten JM, Palanee-Phillips T,...

January 2021: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results

Feb 1, 2021

Article and Study Summary Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study Published in: Lancet. 2020;396 (10267):1994-2005...

ART - antiretroviral therapy